

Date: 31st January, 2025

To, National Stock Exchange of India Limited Exchange Plaza, C-1 Block G, Bandra Kurla Complex Bandra [E], Mumbai – 400051 NSE Scrip Symbol: KRONOX	To, BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 544187
---	--

Subject: Integrated Filing (Financial)- Unaudited Financial Results of KRONOX LAB SCIENCES LIMITED for the Quarter and Nine-Months ended December 31, 2024.

Dear Sir/Madam,


Pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we enclose herewith the Integrated Filing (Financial) including the unaudited standalone financial results of the Company for the quarter and nine- months ended December 31, 2024 ("Results"), along with Limited Review Reports of the Statutory Auditors. The Results are being uploaded on the website of the Company and will also be published in the newspapers.

The Meeting of Board of Directors commenced at 3:30 p.m. and concluded at 4.30 p.m

Kindly take the aforesaid information on your record and oblige.

Thanking you

For **KRONOX Lab Sciences Limited**



Nikhil Goswami
Company Secretary & Compliance Officer
Membership No. A68272



KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.

Registered Office Address : Block No. 353, Village : Ekalbara, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.

Phone No. : +91 2662 244077, 244088

Email : info@kronoxlabsciences.com,

CIN : U24117GJ2008PLC055460

Website : www.kronoxlabsciences.com

CIN : L24117GJ2008PLC055460

KRONOX LAB SCIENCES LIMITED


Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 Gujarat
 email: cs@kronoxlabsciences.com ; CIN: L24117GJ2008PLC055460
 Quarterly & Nine Months ended Financial Result by Companies Other than Banks
Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2024 (Rs In Lakhs)

Sr.No	Particulars	Quarter Ended			Nine Months ended		Year Ended
		31.12.2024	31.12.2023	30.09.2024	31.12.2024	31.12.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
INCOME FROM OPERATION							
1	Revenue from Operation	2,401.11	2,070.96	2,485.91	7,406.28	6,768.60	8,986.24
2	Other Income	81.90	1.53	36.06	161.18	75.19	157.79
3	Total Income	2,483.01	2,072.49	2,521.97	7,567.46	6,843.79	9,144.03
4 EXPENSES							
a	Cost of Materials Consumed	1,254.14	1,002.56	1,087.64	3,570.87	3,280.01	4,489.37
b	Changes in Inventories of Finished Goods, Work in progress and Stock-In-Trade	(66.31)	94.57	41.86	83.80	257.81	96.38
c	Employee Benefits expenses	117.72	134.53	116.31	351.20	501.59	622.85
d	Finance Costs	-	-	-	-	-	-
e	Depreciation and amortisation Expenses	35.72	30.24	34.16	103.12	99.99	128.88
f	Other Expenses	259.08	230.75	359.70	862.72	683.18	945.75
	TOTAL EXPENSES	1,600.35	1,492.65	1,639.67	4,971.71	4,822.58	6,283.22
5	Profit before Tax	882.66	579.84	882.30	2,595.75	2,021.21	2,860.81
6 Tax Expenses							
a	Current Tax	228.97	134.42	225.53	671.16	507.77	734.88
b	Deferred Tax	0.83	(28.26)	9.46	9.40	(33.46)	(9.20)
c	Tax Expenses/Refunds relating to prior years	-	-	-	-	-	-
7	Profit after Tax for the Period	652.86	473.68	647.31	1,915.19	1,546.90	2,135.13
8 Other Comprehensive Income							
a	Item that will not be reclassified to profit or loss	-	-	-	-	-	-
	(i) Defined benefit Plan liability/assets	6.34	5.15	6.01	17.29	17.91	25.51
	(ii) Tax Impact on above item	(1.59)	(1.30)	(1.51)	(4.35)	(4.51)	(5.23)
b	Item that will be reclassified to profit or loss	-	-	-	-	-	-
	(i) Exchange difference arising on translation of foreign operations	-	-	-	-	-	-
c	Exceptional Items	-	-	-	-	-	-
9	Total Comprehensive Income for the period	657.61	477.53	651.80	1,928.13	1,546.30	2,155.41
10	Paid up share capital(FV Rs.10/- per share.)	3710.4	3710.4	3710.4	3710.4	3710.4	3710.4
	Other Equity	-	-	-	-	-	2,920.10
11	Earning per equity share (In Rupees) (F V Rs.10/- per share)	1.77	1.29	1.76	5.20	4.21	5.81
	(Basic & Diluted)						

Notes:

- The above Unaudited results have been prepared in accordance with Indian Accounting Standard (IND AS) notified under section 133 of the companies Act, 2013, read together with relevant rules issued there under and other accounting principles generally accepted in India.
- The above results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and Approved by the Board of Directors in their meeting held on January 31, 2025
- The Company is having only one reportable segment under Ind AS-108 on "Operating Segments" i.e. manufacturing of High Purity Speciality Fine chemical.
- The previous quarters'/years' figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.
- The Company has completed its Initial Public Offer (IPO) being 100% offer for sale of 95,70,000 equity shares of face value of INR 10 each at and issue price of INR 136 per share.(including premium of Rs.126 per share). Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 10th June, 2024.


Date: 31/01/2025
Place: Vadodara



For and on behalf of the Board of
KRONOX LAB SCIENCES LIMITED

Jogindersingh Jaswal

Jogindersingh Jaswal
Chairman & Managing Director
DIN:02385809





Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of KRONOX LAB SCIENCES LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review report to
The Board of Directors
KRONOX LAB SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of KRONOX LAB SCIENCES LIMITED for the quarter ended 31st December 2024 and year to date from April 01, 2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less



assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mahesh Udhwani & Associates
Chartered Accountants
FRN :129738W

M. A. Udhwani



Mahesh Udhwani
Partner

M.N: 047328

UDIN: 25047328BMHXQX9401

Place: Vadodara

Date: 31/01/2025

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable as the Company has done IPO which was 100% Offer For Sale

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Not Applicable for this quarter

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

Not Applicable for this quarter

KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Registered Office Address : Block No. 353, Village : Ekalbara, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Phone No. : +91 2662 244077, 244088
Email : info@kronoxlabsciences.com,
CIN : L24117GJ2008PLC055460
Webside : www.kronoxlabsciences.com